News

Pharmabiz15m
Innovent completes first patient dosing in seventh phase 3 trial (GLORY-OSA) of mazdutide in China with moderate-to-severe OSA & obesity
Innovent completes first patient dosing in seventh phase 3 trial (GLORY-OSA) of mazdutide in China with moderate-to-severe OSA & obesity: San Francisco, US Tuesday, June 17, 2025, ...
Pharmabiz1h
China NMPA accepts and grants priority review status to ArkBio's NDA for Azstarys to treat ADHD in patients aged six years and above
China NMPA accepts and grants priority review status to ArkBio's NDA for Azstarys to treat ADHD in patients aged six years and above: Shanghai, China Tuesday, June 17, 2025, 10:00 ...
Pharmabiz2h
Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease
Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...
Pharmabiz3h
India expands pharma export visibility as ‘Source from India’ platform rolled out for all Status Holder exporters
Shardul Nautiyal, Mumbai Tuesday, June 17, 2025, 08:00 Hrs [IST] ...
Pharmabiz3h
SCDA asks drug regulators to take action against Pill Up e-pharmacy
SCDA asks drug regulators to take action against Pill Up e-pharmacy: Gireesh Babu, New Delhi Tuesday, June 17, 2025, 08:00 Hrs [IST] The South Chemists & Distributors Association ...
Pharmabiz3h
Global pharmaceutical demand is increasingly shifting towards innovative & specialty drugs: Expert
Global pharmaceutical demand is increasingly shifting towards innovative & specialty drugs: Expert: Nandita Vijayasimha, Bengaluru Tuesday, June 17, 2025, 08:00 Hrs [IST] India is ...
Pharmabiz3h
PCI asks institutions to implement AEBAS on immediate basis
The Pharmacy Council of India (PCI) has issued guidelines for the nodal officers and the users in the pharmacy institutions across the country, as the next step to complete the implementation of ...
Pharmabiz17h
Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera
Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...
Pharmabiz18h
EMA’s veterinary medicinal products committee recommends marketing authorization to Elanco’s Zenrelia to treat atopic dermatitis in dogs
EMA’s veterinary medicinal products committee recommends marketing authorization to Elanco’s Zenrelia to treat atopic dermatitis in dogs: Greenfield, Indiana Monday, June 16, ...
Pharmabiz21h
Orbis India sees need to handle preventive ophthalmic issues by incorporating eye screenings into primary healthcare
Orbis India sees the need to advance preventive ophthalmic issues by incorporating eye screenings into primary healthcare. This is because primary care is the first point of contact in the healthcare ...
Pharmabiz20h
Healthcare Summit 2025 hosted by IISc attracts 500 global leaders to focus on future of sector
Healthcare Summit 2025 hosted by IISc attracts 500 global leaders to focus on future of sector: Our Bureau, Bengaluru Monday, June 16, 2025, 14:45 Hrs [IST] Indian Institute of Sc ...
Pharmabiz20h
Lupin & Sino Universal Pharmaceuticals ink license and supply agreement for tiotropium DPI in China
Lupin & Sino Universal Pharmaceuticals ink license and supply agreement for tiotropium DPI in China: Our Bureau, Mumbai Monday, June 16, 2025, 14:30 Hrs [IST] Global pharma major ...